Viatris Reports Third-Quarter 2026 Financial Results

What happened

Viatris reported third-quarter 2026 revenue of $3.75 billion, a U.S. GAAP net loss of $325 million and adjusted EBITDA of $1.20 billion. It said it received U.S. approval for RYZUMVI and Japanese approval for WAKIX, plans to acquire Pacira BioSciences, and raised the midpoints of its 2026 guidance for all metrics.

Confirmed

Global impact / market context

The reported net loss contrasts with positive adjusted EBITDA, a measure of operating performance before certain costs, so investors may distinguish accounting results from the company’s adjusted measure. Higher guidance midpoints signal management expects stronger full-year results, while the planned acquisition could redirect cash and change the business mix.

Analyst inference

The update combines operating results, product approvals, shareholder returns and a planned acquisition. Approvals can support future sales if products reach customers, while returning capital can reduce cash available for other uses. The article gives no deal price, detailed guidance figures or expected financial contribution from the new products.

Analyst inference

What to watch

1. Look for the full 2026 guidance figures and the assumptions behind them; raised midpoints matter only if revenue, costs and other results meet those expectations. Analyst inference
2. Watch whether the planned Pacira BioSciences acquisition closes by the end of November, as stated, and whether the company discloses its price and funding. Proposed
3. Track whether RYZUMVI and WAKIX launches follow their approvals and add sales; the article reports approvals but provides no product revenue forecasts. Analyst inference

Evidence

• Original source link unavailable